Roquefort Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Roquefort Therapeutics has a total shareholder equity of £4.9M and total debt of £609.7K, which brings its debt-to-equity ratio to 12.4%. Its total assets and total liabilities are £6.1M and £1.1M respectively.
Key information
12.4%
Debt to equity ratio
UK£609.70k
Debt
| Interest coverage ratio | n/a |
| Cash | UK£595.66k |
| Equity | UK£4.93m |
| Total liabilities | UK£1.14m |
| Total assets | UK£6.07m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ROQA.F's short term assets (£683.0K) do not cover its short term liabilities (£862.8K).
Long Term Liabilities: ROQA.F's short term assets (£683.0K) exceed its long term liabilities (£281.9K).
Debt to Equity History and Analysis
Debt Level: ROQA.F's net debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ROQA.F's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ROQA.F has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ROQA.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 57.5% each year